Cd8(+) T-Cell Responses to Adeno-Associated Virus Capsid in Humans
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Hepatic adeno-associated virus (AAV)-serotype 2 mediated gene transfer results in transgene product expression that is sustained in experimental animals but not in human subjects. We hypothesize that this is caused by rejection of transduced hepatocytes by AAV capsid-specific memory CD8(+) T cells reactivated by AAV vectors. Here we show that healthy subjects carry AAV capsid-specific CD8(+) T cells and that AAV-mediated gene transfer results in their expansion. No such expansion occurs in mice after AAV-mediated gene transfer. In addition, we show that AAV-2 induced human T cells proliferate upon exposure to alternate AAV serotypes, indicating that other serotypes are unlikely to evade capsid-specific immune responses.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Detection of AAV components by the innate immune system also leads to the AAV-directed adaptive immune response and potential loss of transgene expression in transduced cells (Mingozzi et al., 2007; Xiang et al., 2020).”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Mingozzi et al., 2007
In the citing paper
“Early successes in this field were initially dampened by reports of patients who developed vector insertion-related leukemias directly linked to the viral platform used for transgene delivery11–18.”
From Clonal selection of hematopoietic stem cells after gene therapy for sickle cell disease (2023) · cites this paper as [12]
In the citing paper
“Evidence from early clinical trials, along with subsequent laboratory studies, suggest that CD8+ T cell responses against AAV capsid target transduced hepatocytes (16–18).”
From Effect of CpG Depletion of Vector Genome on CD8+ T Cell Responses in AAV Gene Therapy (2021) · cites this paper as [17]
In the citing paper
“An early clinical trial for the treatment of hemophilia, via i.v. delivery of recombinant AAV (rAAV), resulted in robust CD8 T cell responses and the loss of transgene expression, which was later shown to be mediated by capsid-specific T cell responses.”
From Modulating immune responses to AAV by expanded polyclonal T-regs and capsid specific chimeric antigen receptor T-regulatory cells (2021) · cites this paper as [5]
In the citing paper
“Although AAV infection is non-pathogenic in humans, initial exposure induces humoral and cellular anti-capsid response that are reactive to rAAV due to capsid similarity (4, 5).”
From Immunomodulation in Administration of RAAV: Preclinical and Clinical Adjuvant Pharmacotherapies (2021) · cites this paper as [5]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Self-citationMemory CD8+ T cells vary in differentiation phenotype in different persistent virus infections
Appay, V., Dunbar, P. R., Callan, M., Klenerman, P., Gillespie, G. M. A., Papagno, L., Ogg, G. S., King, A., Lechner, F., Spina, C. A., et al. (2002) · Nature Medicine · doi:10.1038/nm0402-379 · Cited by 1,571
Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy
Gao, G.-P., Alvira, M. R., Wang, L., Calcedo, R., Johnston, J., & Wilson, J. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182412299 · Cited by 1,520
Snyder, R. O., Miao, C., Meuse, L., Tubb, J., Donahue, B. A., Lin, H.-F., Stafford, D. W., Patel, S., Thompson, A. R., Nichols, T., et al. (1999) · Nature Medicine · doi:10.1038/4751 · Cited by 409
Mount, J. D., Herzog, R. W., Tillson, D. M., Goodman, S. A., Robinson, N., McCleland, M. L., Bellinger, D., Nichols, T. C., Arruda, V. R., Lothrop, C. D., et al. (2002) · Blood · doi:10.1182/blood.v99.8.2670 · Cited by 339
Self-citationHeparin binding directs activation of T cells against adeno-associated virus serotype 2 capsid
Vandenberghe, L. H., Wang, L., Somanathan, S., Zhi, Y., Figueredo, J., Calcedo, R., Sanmiguel, J., Desai, R. A., Chen, C. S., Johnston, J., et al. (2006) · Nature Medicine · doi:10.1038/nm1445 · Cited by 208
Wang, L., Nichols, T. C., Read, M. S., Bellinger, D. A., & Verma, I. M. (2000) · Molecular Therapy · doi:10.1006/mthe.2000.0031 · Cited by 176
Identification of mouse AAV capsid-specific CD8+ T cell epitopes
Sabatino, D. E., Mingozzi, F., Hui, D. J., Chen, H., Colosi, P., Ertl, H. C. J., & High, K. A. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.09.009 · Cited by 91
Self-citation
Research works printed but not linked: 1
- Muzyczka, N. & Berns, K.I. Parvoviridae: The Viruses and Their Replication, 2327–2359 (Lippincott Williams & Wilkins, Philadelphia, 2001).
Cited by
Items 701–765 of 765
Adeno‐associated Viral Vectors in Gene Therapy
Li, Z., & Srivastava, A. (2007) · Wiley eBooks · doi:10.1002/9780470015902.a0005738.pub2
Fehlings, M. G. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.734958350.793573257
Helper-Dependent Adenoviral Vectors
Ng, P. (2022) · CRC Press eBooks · doi:10.1201/9781003247432-15
Xu, B., & Haley, R. (2022) · Bioanalysis · doi:10.4155/bio-2022-0162
RetractedHigh, K. A. (2023) · PubMed Central · Cited by 2
Self-citationIntrathecal Delivery of Viral Vector-Mediated Gene Therapy
Keifer, O. P. (2023) · Springer eBooks · doi:10.1007/978-3-031-39558-1_16
Detection of Cellular Immunity to Viral Capsids and Transgene Proteins
de la Rosa, M., & Tary‐Lehmann, M. (2024) · Wiley eBooks · doi:10.1002/9781119852810.ch11
Leclerc, D. (2023) · theses.fr (ABES) · doi:10.70675/265eb7f7zf02bz4293z9d8dz266599d45d4a
Novel therapeutics for diverse neurodegenerative disorders
Chaurasia, R. N., & Favas, T. T. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95735-9.00051-6 · Cited by 1
Caractérisation et immunomodulation de la réponse cellulaire contre les produits de thérapie génique
Avenel, A. (2024) · theses.fr (ABES) · doi:10.70675/f4cd9ee5z09e6z4e26z8edazf0770a51f57c
Comparison of Classical Gene Therapy and Mrna Drug Therapy
Xie, X. (2024) · Journal of medicine and health science. · doi:10.62517/jmhs.202405403
Ding, H., Li, M., Mao, L., Li, B., Hui, W., Zhang, B., & Ban, Q. (2025) · Journal of Visualized Experiments · doi:10.3791/68181
Balasubramanian, A., Prachař, M., Klaproth, B., Copeland, V., Justesen, S. F. L., Wen, Y., Siegel, R. W., & Malherbe, L. P. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1641289 · Cited by 2
Platelet-Mediated Gene and Cell Therapy
Miao, C. H. (2025) · Springer eBooks · doi:10.1007/978-3-031-96360-5_18
AAV-mediated expression of Secreted Klotho as a therapeutic strategy for Alzheimer's disease
Blanch, R. (2023) · Dipòsit Digital de Documents de la UAB (Universitat Autònoma de Barcelona) · Cited by 2
Circulating Biomarkers for Cancer Immunoprofiling
(2018) · Arizona State University Library Digital Repository (Arizona State University)
Genome-Driven Targeted Cancer Therapy
Roshdi Ferdosi, S. (2017) · Arizona State University Library Digital Repository (Arizona State University)
Preclinical Safety and Tolerability of an AAV Vector Expressing TLR9 in Mice and HamstersPreprint
Wootton, S. K., Yang, C., Santos, I., & Thompson, B. (2026) · Research Square · doi:10.21203/rs.3.rs-8545024/v1
Zhan, Y., & Jiang, H. (2026) · Research Square · doi:10.21203/rs.3.rs-8954141/v1
Self-citationApproches de thérapies géniques pour des maladies neuromusculaires
Moulay, G. (2010) · theses.fr (ABES) · doi:10.70675/e7c5d58ez3cc2z4a72z8d92z6b13cb1ea30c · Cited by 1
Approches thérapeutiques pour le traitement de la myopathie myotubulaire
Jamet, T. (2012) · theses.fr (ABES) · doi:10.70675/f5c1d032z0271z4facz8350zddb9b82fafd8
Les vecteurs AAV recombinants : un nouvel outil de vaccination contre les Hénipavirus
Ploquin, A. (2012) · theses.fr (ABES) · doi:10.70675/a11367cfzedd0z46bbz8125zcec139d25083
Gene transfer in the Sandhoff murine model using a specific recombinant AAV9 vector
Niemir, N. (2013) · theses.fr (ABES) · doi:10.70675/f7f92feaz2c9az4447za2f6zb20e4ab539c5
Tanaka, T. (2021) · Institutional Repositories DataBase (IRDB) · doi:10.20776/900119711
Characterisation of AAV capsid-specific CD8+ T cell responses in human subjects
Vandamme, C. (2016) · theses.fr (ABES) · doi:10.70675/371e4bbfze69az417bz960azf9db02287546
Bartolo, L. (2018) · theses.fr (ABES) · doi:10.70675/b32b9711za15dz4740z8481z0ba7dd36e8ee
Etude de la réponse immunitaire virale préexistante anti-AAV chez l'homme
Xicluna, R. (2019) · theses.fr (ABES) · doi:10.70675/d2f47d7cz4f46z448cz85afz657c9516c86f · Cited by 1
Génotoxicité des systèmes CRISPR-Cas9.
Cullot, G. (2019) · theses.fr (ABES) · doi:10.70675/cb1809e4zaafbz4fc1z89e9zeb0e5fd69275
Développement d'un traitement de thérapie génique pour la glycogénose de type III
Vidal, P. (2018) · theses.fr (ABES) · doi:10.70675/5e174471z66d8z44dbza2edz3adc480b1f41
Development of safe and efficient aav vectors for retinal gene therapy
Khabou, H. (2018) · theses.fr (ABES) · doi:10.70675/aa896663z9772z4d87z9bd1z247af1f0e3f1
Journou, M. (2021) · theses.fr (ABES) · doi:10.70675/9a618ac2za0a4z4e90zbdb3ze14482ffa655
Creisméas, A. (2022) · theses.fr (ABES) · doi:10.70675/7e452f5az22a1z433az83a8z1fe23089846a
YY1 Binding Motif Upstream of Rep/Cap Increases AAV Yield and Full CapsidsPreprint
Ofusa, Y., Nishio, S., Enoki, T., Mineno, J., Ozawa, K., Mizukami, H., & Ohba, K. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.21.726733
Han, W., & Zi-Long, Q. I. U. (2026) · Shengming kexue · doi:10.3724/cbls.2026070
Development of a gene-activated matrix for enhanced AAV gene delivery in vitro
Musoski, A., Poulhès, F., Sapet, C., Iqbal, N., Ganguly, P., Kampick, M., Hoechst, B., Marotta, M., Dumler, K., Jha, A., et al. (2026) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2026.1832901
“This is particularly relevant for potential in vivo applications, where immune cell activation can limit transgene expression and therapeutic efficacy (Rey-Rico et al., 2016; Mingozzi et al., 2007).”
Atyeo, N., Warner, B. M., & Chiorini, J. A. (2026) · Oral Oncology · doi:10.1016/j.oraloncology.2026.108071
Host Endoplasmic Reticulum Stress and Interferon Responses Contribute to AAV-Induced Ocular ToxicityPreprint
Gardner, A., Hong, C. M., Zhao, S. R., Daniels, A., & Cepko, C. L. (2026) · eLife · doi:10.7554/elife.111783
Host Endoplasmic Reticulum Stress and Interferon Responses Contribute to AAV-Induced Ocular ToxicityPreprint
Gardner, A., Hong, C. M., Zhao, S. R., Daniels, A., & Cepko, C. L. (2026) · eLife · doi:10.7554/elife.111783.1
abdelnaby, M., Galiakberova, A. A., & Dashinimaev, E. B. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27156846
“These capsid-specific CD8 + T cell responses are dose-dependent, with the magnitude of the T cell response correlating directly with the administered vector dose [13,96].”
InfluentialHu, S., Chen, Y., Wu, C., Reuter, W. H., Deng, J., Jia, N., Walsh, N., Bastille, A., Edwards, T. M. E., Hebben, M., et al. (2026) · Microorganisms · doi:10.3390/microorganisms14081857
“This concern is supported by clinical observations from hemophilia B gene therapy studies, in which AAV capsid-specific CD8+ T-cells responses were associated with loss of transgene expression [38,39] even though the immune response was not directly attributed to rcAAV.”
Batty, P. A., Swystun, L. L., Handyside, B., Ménard, A., Harpell, L., Hurlbut, D., Ismail, A. M., Mo, A., Pender, A., Brennan, S., et al. (2026) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2026.08.014
Hepatotoxicity in Adeno-Associated Virus Gene Therapy: Clinical Challenges and Strategic Solutions
Asai, A., Aqul, A. A., Banc‐Husu, A. M., Diamond, T., Elisofon, S. A., Freeman, A. J., Loomes, K. M., Mohammad, S., Sundaram, S. S., & Chapin, C. A. (2026) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2026.115317
Clinical immunogenicity in rAAV gene therapy: Insights and implications
Gulve, N., Bego, M. G., Gandhi, H., Khan, Z., Tong, O., Katebifar, S., & Rajadhyaksha, M. (2026) · Molecular Therapy Advances · doi:10.1016/j.omta.2026.201848 · Cited by 1
Gene therapies (2015–2025): determinants of translational success
Sackett, J., Jaber, S., Gangapur, P., Biernat, M., & Bao, S. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.118450
Lai, C., Irvin, S. C., Salazar‐Fontana, L. I., Grimaldi, C., Gorovits, B., Xu, Y., & Partridge, M. A. K. (2026) · The AAPS Journal · doi:10.1208/s12248-026-01303-1 · Cited by 1
MADCAP: isolation of novel nAb-naïve AAV capsids from metagenomic data
Lyashenko, E., Torregrosa, T., Ysasi, A. B., Wu, J. T., Bu, J., Hennessy, M., Na, Y., Ryan, M. J., Takar, M., Manek, R., et al. (2026) · Journal of Virology · doi:10.1128/jvi.00630-26 · Cited by 1
In vivo CAR-T cell generation: a production-rate framework linking vector and cellular pharmacology
Hu, J., Zhu, D., & Zheng, S. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1939127
“Pre-existing humoral immunity can reduce productive vector exposure after systemic administration, whereas capsid-speci fi c cellular immune responses may further constrain persistence and redosing (57, 58).”
Wang, Z., Wu, N., Fu, D., Zhao, Q., & Wang, H. (2026) · Scientific Reports · doi:10.1038/s41598-026-71872-w
Ding, Q., Zhou, X., Olson, E. N., & Liu, N. (2026) · Vascular Pharmacology · doi:10.1016/j.vph.2026.107709
Bovine AAV: A promising vector for pulmonary gene therapy
Ivan, D. C., Dubost, V., Israël, L., Weinmann, J., Ungan, D., Carbonetti, N., Stuber, N., Jivkov, M., Erard, E., Biglieri, E., et al. (2026) · Molecular Therapy Advances · doi:10.1016/j.omta.2026.201859
Development and application of non-integrating lentiviral vectors for gene therapy
Apolonia, L. (2009) · UCL Discovery (University College London) · Cited by 1
A study of intracoronary gene transfer using stents coated with plasmid vectors
Williams, P. D. (2011) · Research Explorer (The University of Manchester)
Fargnoli, A. S. (2014) · ScholarlyCommons (University of Pennsylvania)
(1999) · doi:10.1002/1529-0131(199901)42:1<76::aid-anr10>3.0.co;2-g
Metadata
- Authors
- Mingozzi, F., Maus, M. V., Hui, D. J., Sabatino, D. E., Murphy, S. L., Rasko, J. E. J., Ragni, M. V., Manno, C. S., Sommer, J., Jiang, H., Pierce, G. F., Ertl, H. C. J., & High, K. A.
- Affiliations
- Children's Hospital of Philadelphia (US)
- The University of Sydney (AU)
- Hemophilia Center of Western Pennsylvania (US)
- The Wistar Institute (US)
- Corresponding author
- High, Katherine A
- ORCID
- Venue
- Nature Medicine
- Published
- 2007-03-18
- Volume
- 13
- Issue
- 4
- Pages
- 419-422
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2007261697
- Cited by
- 748
- References
- 8
- Citations by year
- 2026: 34 · 2025: 43 · 2024: 43 · 2023: 41 · 2022: 34 · 2021: 58 · 2020: 43 · 2019: 40 · 2018: 28 · 2017: 38 · 2016: 24 · 2015: 40 · 2014: 41 · 2013: 37 · 2012: 40
- FWCI
- 22.15
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (1f32hl069647-01)
- National Heart, Lung, and Blood Institute (F32 HL69647, P01HL078810, T32HL007439)
- National Institute of Allergy and Infectious Diseases (P30AI045008)
- National Institute of Diabetes and Digestive and Kidney Diseases (T32DK007748)
- National Center for Research Resources (M01RR000056, M01RR000240)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- adeno-associated virus, AAV capsid, CD8+ T cells, AAV serotype 2, gene transfer, T cell memory, T cell proliferation
- MeSH terms
- Dependovirus, Animals, Capsid, Humans, Lymphocyte Activation, Parvoviridae Infections, Peptides, Gene Transfer Techniques, CD8-Positive T-Lymphocytes, Hepatocytes, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.